Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIP-203
- Development stage
- Preclinical
- Lead developer
- AIP
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AIP-203 is a therapeutic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP Medical) for the treatment of blood cancers. As a radiopharmaceutical, it is designed to deliver targeted ionizing radiation directly to malignant cells, thereby minimizing damage to surrounding healthy tissues. The drug is currently in the preclinical/IND-enabling stage of development. While the specific molecular target and therapeutic radioisotope have not been publicly disclosed, AIP-203 is part of a broader oncology pipeline at AIP Medical focused on leveraging novel diagnostic and therapeutic radiopharmaceutical innovations.
Beyond the preview
Go deeper on AIP-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIP-203.